LONDON--(BUSINESS WIRE)--The global sickle cell disease treatment market is poised to grow by USD 1.85 billion during 2019-2023, progressing at a CAGR of over 11% during the forecast period. Request Free Sample Pages
Read the 112-page research report with TOC on "Sickle Cell Disease Treatment Market Analysis Report by Indication (Sickle cell anemia, Sickle cell beta thalassemia, and Others), by Geography (North America, Europe, Asia, and ROW), and Segment Forecasts, 2019 - 2023"
The market is driven by the high prevalence of sickle cell disease. In addition, the advent of regenerative therapy is anticipated to further boost the growth of the sickle cell disease treatment market.
In the last few years, the sickle cell trait had increased significantly among patients, resulting in the rising number of sickle cell disease cases. It is more prevalent among African-Americans and the number of patients affected by this disease is expected to increase significantly. These factors will increase the demand for sickle cell disease treatment, which will boost market growth during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Major Five Sickle Cell Disease Treatment Market Companies:
ADDMEDICA operates businesses under the pharmaceuticals and medical devices segments. The treatment offered by the company is Siklos. It is a hydroxyurea-based treatment for pediatric patients with sickle cell anemia.
Bristol-Myers Squibb operates the business under the segment, biopharmaceuticals. The company’s key offering includes DROXIA (hydroxyurea capsules) which is available for oral use as capsules with 200 mg, 300 mg, and 400 mg hydroxyurea. It is an antimetabolite used to reduce the frequency of pain and the rate of blood transfusion in patients with sickle cell anemia.
Emmaus Medical has business operations under the pharmaceuticals segment. The treatment offered by the company is Endari (L-glutamine oral powder) which is used for the reduction of acute complications associated with sickle cell disease in patients aged five years and older. It is available in 5 grams of L-glutamine powder per paper-foil-plastic laminate packet.
Novartis operates the business under three segments, which include innovative medicines, Sandoz, and Alcon. The company’s key offering includes Crizanlizumab. It is a P selectin inhibitor that is being studied in Phase III of clinical trials for the treatment of sickle cell anemia.
Pfizer operates the business under the following segments: innovative health and essential health. The company’s key offering in the sickle cell disease treatment market include Rivipansel. It is a pan-selectin inhibitor that is being developed in partnership with GlycoMimetics to treat the vaso-occlusive pain caused by sickle cell disease.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Sickle Cell Disease Treatment Indication Outlook (Revenue, USD Million, 2019 - 2023)
- Sickle cell anemia
- Sickle beta thalassemia
Sickle Cell Disease Treatment Regional Outlook (Revenue, USD Million, 2019 - 2023)
- North America
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on HealthCare include:
Hemoglobinopathies Treatment Market – Global Hemoglobinopathies Treatment Market by type (sickle cell disease and thalassemia) and geography (the Americas, APAC, and EMEA).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org